Transcriptomic expression of A549 cells treated with palbociclib and indisulam or PF-06873600 and SUM159 cells treated with PF-06873600

Inducing senescence in cancer cells is emerging as a new therapeutic strategy. We tested the senescence induction of palbociclib and indisulam or PF-06873600 in A549 and PF-06873600 in SUM159 cells, and profiled these for senescence associated gene signatures. Overall design: Transcriptomic analysis of A549 cells treated with palbociclib and indisulam or PF-06873600 and SUM159 cells treated with PF-06873600 and controls. The experiment was performed in technical duplicates. A549 cells were treated with 2µM Palbociclib, 0.5µM of indisulam and the combniation for 10 days. A549 and SUM159 were treated with 0.5µM PF-06873600 for 7 days.

诱导癌细胞衰老已成为新兴的癌症治疗策略。本研究检测了帕博西尼（palbociclib）、吲达沙林（indisulam）或PF-06873600对A549细胞的衰老诱导效果，以及PF-06873600对SUM159细胞的衰老诱导效果，并对上述样本的衰老相关基因特征（senescence associated gene signatures）进行了表征分析。
实验整体设计：对经帕博西尼联合吲达沙林、单药帕博西尼、单药PF-06873600处理的A549细胞，以及经PF-06873600处理和对照组处理的SUM159细胞开展转录组分析（transcriptomic analysis）。本实验设置技术重复（technical duplicates）。其中，A549细胞分别以2μM帕博西尼、0.5μM吲达沙林以及二者联合方案处理10天；A549与SUM159细胞均以0.5μM PF-06873600处理7天。